4'-[2-羟基-3-(4-苯基哌嗪基)丙氧基]查耳酮 | 63937-18-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 中文名称: 4'-[2-羟基-3-(4-苯基哌嗪基)丙氧基]查耳酮
• 英文名称: 4'-(2-Hydroxy-3-(4-phenylpiperazinyl)propoxy)chalcone
• 英文别名: (E)-3-[4-[2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy]phenyl]-1-phenylprop-2-en-1-one
• CAS: 63937-18-8
• 化学式: C₂₈H₃₀N₂O₃
• 分子量: 442.558
• InChiKey: YWWWPDNCUYNBFG-DTQAZKPQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (E)-3-(4-羟基苯基)-1-苯基丙-2-烯-1-酮 在 sodium hydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 4'-[2-羟基-3-(4-苯基哌嗪基)丙氧基]查耳酮
  参考文献：
  名称：

  Chalcone based aryloxypropanolamines as potential antihyperglycemic agents

  摘要：

  A series of chalcone based aryloxypropanolamines were synthesized and evaluated for their antihyperglycemic activity in SLM and STZ rat models. Most of the compounds exhibited moderate to good activity ranging from 6.5% to 31.1% in SLM and 8.3% to 22.6% in STZ models, respectively. The most potent compound 5g exhibited glucose lowering of 26.7% in SLM and 22.6% in STZ models. A definite structure-activity relationship was observed while varying the nature as well as the position of the amine in ring B. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.068

文献信息

• Chalcone based aryloxypropanolamines as potential antihyperglycemic agents
  作者：Poonam Shukla、Amar Bahadur Singh、Arvind Kumar Srivastava、Ram Pratap

  DOI：10.1016/j.bmcl.2006.10.068

  日期：2007.2

  A series of chalcone based aryloxypropanolamines were synthesized and evaluated for their antihyperglycemic activity in SLM and STZ rat models. Most of the compounds exhibited moderate to good activity ranging from 6.5% to 31.1% in SLM and 8.3% to 22.6% in STZ models, respectively. The most potent compound 5g exhibited glucose lowering of 26.7% in SLM and 22.6% in STZ models. A definite structure-activity relationship was observed while varying the nature as well as the position of the amine in ring B. (c) 2006 Elsevier Ltd. All rights reserved.